Sam,
I can see your point across posts. You hate gene-company.
>> Regeneron is a one man show, namely George Yancapolos, the chief scientist.<<
Pure George, in a day shift he is working in lab, and in night-shift at plant to satisfy Merck requirement!
>> While his science is phenomenal, the company's approach of product development is
dismal. I just don't see how they can get even 0.1 product to the market given their
current pipeline.<<
Must be that you are experts in CNTF toxicity, and BDNF BBB-delivery. Apply for job at REGN, I assume you are student medicine, and fix it.
>> While his science is phenomenal, the company's approach of product development is
dismal. I just don't see how they can get even 0.1 product to the market given their
current pipeline.<<
What is your magic-ball predicting what will be relevant in biotechnology?
>> April 5 announcement of MAP kinase is a non-event. There are so many kinases. Just
in the map kinase family there are : MAP kinase substrates,Map kinase, map kinase
kinase, map kinase kinase kinase, and map kinase kinase kinase kinase.<<
How many protease are there?: protease, protease, protease,.......protease, protease, .....
>> It is an intracellular protein and it will not be
possible to use it for any disease. It is not even so interesting scientifically.<<
ICAM-1 is also intracellular adhesion protein, very relevant, but probably you didn't hear about, or according to you it is irrelevant!
mz |
